Document Detail


Bone response to termination of oestrogen treatment.
MedLine Citation:
PMID:  78095     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Forty-three oophorectomised patients were reviewed 8 years after their initial attendance at a research clinic investigating the aetiology and prevention of postmenopausal osteoporosis. Fifteen patients who had been treated with an oestrogen did not lose a significant amount of bone during the 8 years of therapy. Patients in the placebo-treated control group initially had bone loss of 2.6% per annum, which later fell to an average of 0.75% per annum. Fourteen patients who had been treated with oestrogen for the first 4 years lost no bone, but on withdrawal of oestrogen their bone mineral content fell over the next 4 years at an average rate of 2.5% per annum. 8 years after their initial attendance there was no significant difference between this group and patients who had received placebo for the full 8 years. The result of this study indicates that long-term prevention of bone loss by oestrogens has important medical, social, economic implications.
Authors:
R Lindsay; D M Hart; A MacLean; A C Clark; A Kraszewski; J Garwood
Related Documents :
23266205 - Efficacy of a modified technique for tvt-o positioning: a twelve-month, randomized, sin...
16182025 - Bone setting for prolonged neck pain: a randomized clinical trial.
15889315 - Changes in bone mineral density, body composition and biochemical markers of bone turno...
11069195 - Predicting subsequent bone density response to intermittent cyclical therapy with etidr...
22007035 - Abnormal response of superior sinoatrial node to sympathetic stimulation is a character...
19858955 - Factors associated with long hospital length of stay in patients receiving warfarin aft...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1978 Jun 
Date Detail:
Created Date:  1978-08-28     Completed Date:  1978-08-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1325-7     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone and Bones / drug effects*
Castration
Female
Follow-Up Studies
Humans
Menopause*
Mestranol / administration & dosage*,  therapeutic use
Middle Aged
Osteoporosis / prevention & control*
Placebos
Substance Withdrawal Syndrome / prevention & control*
Time Factors
Chemical
Reg. No./Substance:
0/Placebos; 72-33-3/Mestranol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Heart-rates of surgeons during operations and other clinical activities and their modification by ox...
Next Document:  Impairment of the immune response to vaccination after acute malaria.